{"id":"anlotinib-and-tqb2450-solution","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypertension"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Immune-related adverse events"},{"rate":null,"effect":"Hand-foot skin reaction"}]},"_chembl":{"chemblId":"CHEMBL4303201","moleculeType":"Small molecule","molecularWeight":"407.45"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This combination targets both the tumor microenvironment and immune checkpoint pathways. Anlotinib is a multi-target tyrosine kinase inhibitor that blocks VEGFR, FGFR, and other kinases involved in angiogenesis and tumor proliferation. TQB2450 blocks the PD-L1/PD-1 interaction, releasing T-cell exhaustion and promoting anti-tumor immunity. The combination aims to synergistically reduce tumor growth through dual mechanisms.","oneSentence":"Anlotinib inhibits multiple receptor tyrosine kinases to block tumor angiogenesis and growth, while TQB2450 is a PD-L1 inhibitor that enhances anti-tumor immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:41.058Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (under investigation in Phase 3)"}]},"trialDetails":[{"nctId":"NCT04665609","phase":"PHASE3","title":"Thermal Ablation Combined With Anlotinib and TQB2450 Solution for HCC","status":"UNKNOWN","sponsor":"Chinese PLA General Hospital","startDate":"2021-03-05","conditions":"Hepatocellular Carcinoma, Thermal Ablation, Anlotinib","enrollment":80}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Anlotinib and TQB2450 solution","genericName":"Anlotinib and TQB2450 solution","companyName":"Chinese PLA General Hospital","companyId":"chinese-pla-general-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Anlotinib inhibits multiple receptor tyrosine kinases to block tumor angiogenesis and growth, while TQB2450 is a PD-L1 inhibitor that enhances anti-tumor immune response. Used for Non-small cell lung cancer, Other solid tumors (under investigation in Phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}